US20140147515A2 - Methods And Compositions For Controlling Parasitic Infections Of Animals - Google Patents

Methods And Compositions For Controlling Parasitic Infections Of Animals Download PDF

Info

Publication number
US20140147515A2
US20140147515A2 US11/571,053 US57105306A US2014147515A2 US 20140147515 A2 US20140147515 A2 US 20140147515A2 US 57105306 A US57105306 A US 57105306A US 2014147515 A2 US2014147515 A2 US 2014147515A2
Authority
US
United States
Prior art keywords
composition
derived
yeast
preparation
oregano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/571,053
Other versions
US20080008767A1 (en
US8992999B2 (en
Inventor
Cepta Duffy
Aidan Joseph Connolly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alltech Corp
Original Assignee
Alltech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US11/571,053 priority Critical patent/US8992999B2/en
Application filed by Alltech Corp filed Critical Alltech Corp
Priority claimed from PCT/US2004/023478 external-priority patent/WO2006022616A1/en
Publication of US20080008767A1 publication Critical patent/US20080008767A1/en
Assigned to ALLTECH, INC. reassignment ALLTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DUFFY, CEPTA
Assigned to ALLTECH, INC. reassignment ALLTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CONNOLY, AIDAN
Assigned to COOPERATIEVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A., "RABOBANK NEDERLAND", NEW YORK BRANCH, AS ADMINISTRATIVE AGENT reassignment COOPERATIEVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A., "RABOBANK NEDERLAND", NEW YORK BRANCH, AS ADMINISTRATIVE AGENT SECURITY AGREEMENT Assignors: ALLTECH, INC.
Assigned to BANK OF AMERICA, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT reassignment BANK OF AMERICA, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT INTELLECTUAL PROPERTY SECURITY INTEREST ASSIGNMENT AGREEMENT (PATENTS) Assignors: COOPERATIEVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A., "RABOBANK NEDERLAND", NEW YORK BRANCH, AS RESIGNING ADMINISTRATIVE AGENT
Publication of US20140147515A2 publication Critical patent/US20140147515A2/en
Publication of US8992999B2 publication Critical patent/US8992999B2/en
Application granted granted Critical
Assigned to WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT reassignment WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT ASSIGNMENT FOR SECURITY -- PATENTS Assignors: ALLTECH, INC, RIDLEY USA, INC
Assigned to ALLTECH, INC., Ridley USA Inc. reassignment ALLTECH, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Assigned to ALLTECH, INC. reassignment ALLTECH, INC. TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS (4) Assignors: BANK OF AMERICA, N.A., AS SUCCESSOR AGENT TO COOPERATIVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A., "RABOBANK NEDERLAND", NEW YORK BRANCH, AS ADMINISTRATIVE AGENT
Assigned to BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT reassignment BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT PATENT SECURITY AGREEMENT Assignors: ALLTECH, INC.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/10Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/30Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/163Sugars; Polysaccharides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/70Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75Feeding-stuffs specially adapted for particular animals for birds for poultry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/062Ascomycota
    • A61K36/064Saccharomycetales, e.g. baker's yeast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Definitions

  • This invention relates broadly to novel compositions and methods for controlling parasitic diseases of animals.
  • the invention relates to compositions and methods for controlling protozoal parasitic infections of animals.
  • the invention relates to compositions and methods for reducing the harmful effects of protozoal parasitic infections in animals.
  • Protozoal parasitic infections of food species including mammals and birds are characterized by varying degrees of enteritis that results in decreased production and performance. In extreme cases, increased mortality is seen. However, even in less severe infections, losses in feed conversion efficiency and decreased weight gains may represent the difference between profit and loss in modern, intensive animal production situations.
  • coccidial infections are known to be a predisposing factor to other syndromes, in particular necrotic enteritis (a bacterial infection of the intestinal lining resulting in necrosis of the intestinal lining in various regions of the gut).
  • necrotic enteritis a bacterial infection of the intestinal lining resulting in necrosis of the intestinal lining in various regions of the gut.
  • Other protozoans such as Histomonas and Cochlosoma, also lead to necrotic enteritis and increased mortality in severe cases, or in less severe cases poor feed utilization, stunted growth, and overall poor performance. The economic effects on producers can be catastrophic. It is standard poultry industry practice to reuse litter. However, such reused litter may serve
  • Anti-protozoal drugs are generally effective for their intended purpose, and advantageously may be provided in the feed or via the drinking water to animals being treated.
  • a significant disadvantage of current drugs used for treatment/control of protozoa is that, over time, treated organisms may become resistant to particular drugs. Accordingly, different drugs must be used, often in rotation or in a staggered schedule (shuttle programs), to prevent development of resistant organisms. Even in cases where shuttle programs are implemented, it is possible that efficacy against protozoal infections will be compromised during the period when drugs are altered.
  • certain drugs while useful in the control of protozoa, require a predetermined withdrawal period prior to slaughter to allow sale of meat, milk, eggs, etc. from treated animals.
  • compositions for preventing or reducing harmful effects of a protozoal infection in an animal suffering from or exposed to a protozoal organism, the composition comprising a yeast cell wall and a preparation derived from oregano.
  • the compositions of the present invention are effective against a variety of protozoal infections, including those caused by protozoal organism selected from Eimeria species, Histomonas species, Cochlosoma species, Hexamita species, and combinations thereof.
  • the compositions may be formulated for admixing with food, or may be provided as a dietary supplement.
  • the oregano preparation may be derived by any means known in the art.
  • the oregano preparation comprises at least one oil derived from oregano by steam distillation.
  • the compositions may comprise at least one yeast-derived mannanoligosaccharide, wherein the mannanoligosaccharide-containing composition is formulated for feeding to any animal, including bovine, porcine, avian, equine, ovine, lapine, caprine, and aquatic species.
  • the composition may be formulated for feeding to avian species such as a chicken, turkey, duck, goose, pheasant, quail or a companion bird.
  • the yeast may be Saccharomyces, Candida, Kluyveromyces and Torulaspora, or any combination thereof.
  • the yeast is derived from Saccharomyces cerevisiae.
  • the yeast is derived from Saccharomyces cerevisiae strain NCYC 1026.
  • the compositions may comprise dried cells of yeast.
  • compositions of the present invention may further comprise at least one mineral nutrient.
  • the mineral nutrient may be selected from at least one of selenium or zinc.
  • the compositions may comprise a preparation derived from a Yucca plant.
  • the Yucca plant preparation may be derived by chopping, crushing, macerating, pressing, or grinding the Yucca plant to obtain an extract.
  • compositions for preventing or reducing harmful effects of a protozoal infection in an animal, the compositions comprising a yeast cell wall, at least one preparation derived from oregano, and at least one plant preparation derived from Yucca.
  • the yeast cell wall, oregano preparation, and Yucca plant preparation are substantially as described above.
  • the composition may further comprise at least one mineral nutrient, selected from at least one of selenium or zinc.
  • the compositions may be formulated for admixing with a food, or for feeding as a dietary supplement.
  • a method for preventing or reducing harmful effects of a protozoal infection in an animal suffering from or exposed to a protozoal organism comprising administering a composition to the animal comprising a yeast cell wall and a preparation derived from oregano in an amount effective to prevent or reduce protozoal infection or cecal or liver lesions caused by protozoal infection.
  • the compositions may be formulated for admixing with a food, or for feeding as a dietary supplement.
  • a method for preventing or reducing harmful effects of a protozoal infection in an animal comprising administering a composition to the animal comprising a yeast cell wall, at least one preparation derived from oregano, and at least one plant preparation derived from Yucca in an amount effective to prevent or reduce protozoal infection or cecal lesions caused by protozoal infection.
  • compositions and methods for controlling protozoal parasitic infections are provided.
  • the present invention provides novel compositions for controlling protozoal parasitic infections, comprising a yeast cell wall and a preparation derived from oregano.
  • the yeast cell wall includes at least one mannanoligosaccharide, and the oregano preparation is an oil.
  • the compositions of this invention as described herein may be fed as supplements, or may be incorporated into commercially available foodstuffs.
  • the amounts of the composition fed will vary depending upon the animal species, the size of the animal, and the type of foodstuff to which the composition is added.
  • the methods of the invention as described herein are suitable for preventing or reducing the harmful effects of protozoal parasitic infections in animals, including but not limited to, bovine, porcine, avian, equine, ovine, lapine, caprine, and aquatic species.
  • the yeast cell wall is prepared from a yeast organism using known methodology (see, Peppler, H. J. 1979. Production of yeasts and yeast products. Page 157 in: Microbial Technology & Microbial Processes, Vol. 1 (2d Ed.), Academic Press; incorporated herein by reference). Briefly, a yeast organism (typically S. cerevisiae strain NCYC 1026) is grown in accordance with common techniques used in food/beverage-related fermentations. Any of a number of common sugar-containing media, such as diluted molasses, may be used to provide a source of sugars for growth of the yeasts. Other suitable media include wood sugars, sulfite waste liquor, and whey. The yeast biomass may then be separated and washed by centrifugation.
  • the organism may be lysed by common methods, such as autolysis and/or hydrolysis at room temperature and pressure.
  • a protease such as papain or any of a number of alkaline or neutral proteases may be added during the lysis phase to accelerate solubilization of yeast proteins and prevent agglutination of intracellular components.
  • the resultant yeast cell wall preparation may be washed, such as by centrifugation and resuspension in a wash solution, and concentrated.
  • the concentrated cell wall may be dried by any suitable method, such as drum drying or spray drying, to form a hygroscopic, water-soluble product.
  • the Yucca preparation may be derived from a Yucca plant by any suitable method for deriving a liquid extract from the plant, such as by chopping, crushing, macerating, pressing, or grinding the Yucca plant and obtaining a liquid extract therefrom.
  • the bark of the Yucca may be removed prior to extracting the liquid.
  • the liquid extract may be converted to powder form for storage and/or transport, such as by drying and optionally admixing with a suitable carrier, prior to addition to the compositions of the present invention.
  • an organic or chelated trace mineral formulation will be used.
  • the Se component may be provided as an organic Se source (SEL-PLEX; Alltech, Inc., Nicholasville, Ky.) and the Zn component may be provided as BIOPLEX ZN (Alltech, Inc., Nicholasville, Ky.).
  • SEL-PLEX organic Se source
  • BIOPLEX ZN BIOPLEX ZN
  • any formulation of trace mineral suitable for provision as a food/feed ingredient or supplement may be used in the compositions of the present invention.
  • compositions of the present invention Anticoccidial efficacy of the compositions of the present invention in poultry was evaluated against a conventional coccidiostat, Salinomycin (60 g/1000 kg of feed). Three dietary treatments were prepared:
  • a coccidial inoculum was prepared, consisting of a mixed species culture of oocysts of Eimeria acervulina (60,000 oocysts), E. maxima (10,000 oocysts), and E. tenella (50,000 oocysts).
  • the inoculum was delivered to birds receiving a coccidial challenge by oral gavage in a volume of 1 ml per bird in water.
  • Table 1 summarizes the effect of the present invention on live weight gain and feed conversion.
  • the compositions of the invention (dietary treatments 2 and 3) provided significant increases in weight gain in inoculated birds, compared to nontreated and inoculated controls. There was no statistically significant effect on feed conversion.
  • compositions of the present invention reduced the severity of intestinal lesions (Table 2) compared to nonmedicated, challenged groups. Lesion scores were observed and recorded according to the system of Johnson and Reid (Johnson, J. K., Reid, W. M. 1970. Anticoccidial drugs: lesion scoring techniques in battery and floor pen experiments with chickens. Exp. Parasitol. 28, 30-36; incorporated herein by reference), wherein 0 is normal and severity of lesions is ranked from 1-4, with 4 representing the most severe infection.
  • Blackhead is an acute or chronic protozoan disease of fowl, primarily affecting the cecae and liver, caused by Histomonas meleagridis. Symptoms include loss of appetite, increased thirst, drowsiness, and diarrhea.
  • the basal feed was a commercial corn-soy based diet. Starter feed was fed from day 0 to 21 of the experiment, and grower feed was fed from day 22 to 42. Diet 1 and diet 2 from Example 1 above were added to the basal diet as premixes (1.9 kg/ton). The conventional medicated feed premix Histostat (nitarsone, 170.3 g/ton) was added as a positive control.
  • the basal diet composition is presented in Table 3.
  • H. gallinarum cecal worm
  • contaminated litter was top dressed (approximately 2 pounds/pen/day) in 4 of the 5 pens.
  • the fifth pen was kept as an unchallenged control.
  • the animals were visually inspected daily for general health and response to challenge. After day 7, all animals were observed for clinical signs of infection.
  • days 28, 35, and 42 25 randomly selected birds were euthanized, and cecal and liver lesions scored as follows:
  • Treatments were: (1) non-challenged (with H. meleagridis ) non-supplemented; (2) challenged but non-supplemented; (3) challenged and provided Histostat; (4) challenged and provided dietary treatment 1 as described in Example 1; and (5) challenged and provided dietary treatment 2 as described in Example 1. Results are presented in Tables 4-9.
  • Treatment Day 28 Day 35 Day 42 1 0.000 a 0.000 a 0.000 a 0.000 a 2 0.760 b 1.160 c 0840 b 3 0.000 a 0.000 a 0.040 a 4 0.040 a 0.320 b 0.080 a 5 0.040 a 0.240 b 0.000 a
  • Feed consumption was greatest for the unchallenged group and lowest for the group provided Histostat.
  • Feed efficiency calculated as feed consumption through a period by weight gained, was greatest in the unchallenged group through days 28 and 35.
  • Feed efficiency was greatest on day 42 in the group provided dietary treatment 2.
  • mortality was lowest in the unchallenged group and in the group provided dietary treatment 2.
  • cecal lesions were significantly higher in the group provided Histostat than in the group provided dietary treatment 2. Cecal lesions were less severe in birds provided the composition of the present invention in comparison to the birds receiving Histostat.
  • the results of the present experiment suggest that birds challenged with H. meleagridis and provided the compositions of this invention performed in a similar manner as birds provided a commercial medicated feed, and significantly better than untreated challenged birds.
  • Cochlosoma anatis is a flagellated protozoan parasite of birds, which is considered a primary source of loss performance and mortality in turkeys.
  • the purpose of this experiment was to compare the effects of the compositions of the present invention to conventional treatments for C. anatis, specifically Histostat (170.3 g/ton of feed) and monensin (72 g/ton of feed) provided as premixes.
  • C. anatis inoculum was prepared as follows:
  • Treatments were: (1) non-challenged (with C. anatis ) non-supplemented; (2) challenged non-supplemented; (3) challenged and provided Histostat; (4) challenged and provided monensin; (5) challenged and provided dietary treatment 1 from Example 1; and (6) challenged and provided dietary treatment 2 from Example 1. Results are presented in Tables 11-15.
  • compositions of the present invention gave similar results in comparison to conventional medicated preparations for treatment of C. anatis.
  • the present invention provides suitable compositions and methods for control or reduction of harmful effects of various protozoal parasites of animals.
  • the compositions are efficacious, and provide a level of control of protozoal infections comparable to that of conventional drug-based treatments.

Abstract

A composition for preventing or reducing harmful effects of protozoal infection is provided, comprising in one embodiment a yeast cell wall and a preparation derived from oregano. The composition may further include a mineral nutrient selected from selenium and/or zinc. The composition may also include a preparation derived from Yucca. Efficacy of the composition is shown against a variety of protozoal organisms.

Description

    TECHNICAL FIELD
  • This invention relates broadly to novel compositions and methods for controlling parasitic diseases of animals. In particular, the invention relates to compositions and methods for controlling protozoal parasitic infections of animals. Still further, the invention relates to compositions and methods for reducing the harmful effects of protozoal parasitic infections in animals.
  • BACKGROUND OF THE INVENTION
  • Protozoal parasitic infections of food species including mammals and birds are characterized by varying degrees of enteritis that results in decreased production and performance. In extreme cases, increased mortality is seen. However, even in less severe infections, losses in feed conversion efficiency and decreased weight gains may represent the difference between profit and loss in modern, intensive animal production situations. For example, coccidial infections are known to be a predisposing factor to other syndromes, in particular necrotic enteritis (a bacterial infection of the intestinal lining resulting in necrosis of the intestinal lining in various regions of the gut). Other protozoans, such as Histomonas and Cochlosoma, also lead to necrotic enteritis and increased mortality in severe cases, or in less severe cases poor feed utilization, stunted growth, and overall poor performance. The economic effects on producers can be catastrophic. It is standard poultry industry practice to reuse litter. However, such reused litter may serve as a protozoal reservoir for future infections.
  • Conventional disinfectants are relatively ineffective against protozoans. Thus, thorough cleaning of housing and strict biosecurity measures are necessary to maintain proper hygiene standards and reduce animal exposure. Unfortunately, due to relatively rapid turnaround of hosts (for example, the rapid replacement of flocks in broiler operations), a permanent reservoir of protozoal organisms is often maintained. Even a few organisms are capable of massive multiplication in a few weeks time. Accordingly, control measures beyond maintenance of proper hygiene are required.
  • Currently known methods of protozoal control include use of anti-protozoal medication. Anti-protozoal drugs are generally effective for their intended purpose, and advantageously may be provided in the feed or via the drinking water to animals being treated. However, a significant disadvantage of current drugs used for treatment/control of protozoa is that, over time, treated organisms may become resistant to particular drugs. Accordingly, different drugs must be used, often in rotation or in a staggered schedule (shuttle programs), to prevent development of resistant organisms. Even in cases where shuttle programs are implemented, it is possible that efficacy against protozoal infections will be compromised during the period when drugs are altered. Additionally, certain drugs, while useful in the control of protozoa, require a predetermined withdrawal period prior to slaughter to allow sale of meat, milk, eggs, etc. from treated animals.
  • There thus remains a need in the art for alternative methods for controlling protozoal infections in animals and birds. There is further a need in the art for alternative methods for controlling protozoa which do not risk creating resistant organisms.
  • SUMMARY OF THE INVENTION
  • In accordance with the purposes of the present invention as described herein, in one aspect of the present invention compositions are provided for preventing or reducing harmful effects of a protozoal infection in an animal suffering from or exposed to a protozoal organism, the composition comprising a yeast cell wall and a preparation derived from oregano. The compositions of the present invention are effective against a variety of protozoal infections, including those caused by protozoal organism selected from Eimeria species, Histomonas species, Cochlosoma species, Hexamita species, and combinations thereof. The compositions may be formulated for admixing with food, or may be provided as a dietary supplement. The oregano preparation may be derived by any means known in the art. In one embodiment, the oregano preparation comprises at least one oil derived from oregano by steam distillation.
  • The compositions may comprise at least one yeast-derived mannanoligosaccharide, wherein the mannanoligosaccharide-containing composition is formulated for feeding to any animal, including bovine, porcine, avian, equine, ovine, lapine, caprine, and aquatic species. The composition may be formulated for feeding to avian species such as a chicken, turkey, duck, goose, pheasant, quail or a companion bird. The yeast may be Saccharomyces, Candida, Kluyveromyces and Torulaspora, or any combination thereof. In one embodiment of the present invention, the yeast is derived from Saccharomyces cerevisiae. Typically, the yeast is derived from Saccharomyces cerevisiae strain NCYC 1026. The compositions may comprise dried cells of yeast.
  • The compositions of the present invention may further comprise at least one mineral nutrient. The mineral nutrient may be selected from at least one of selenium or zinc. Still further, the compositions may comprise a preparation derived from a Yucca plant. The Yucca plant preparation may be derived by chopping, crushing, macerating, pressing, or grinding the Yucca plant to obtain an extract.
  • In another aspect of the present invention, compositions are provided for preventing or reducing harmful effects of a protozoal infection in an animal, the compositions comprising a yeast cell wall, at least one preparation derived from oregano, and at least one plant preparation derived from Yucca. The yeast cell wall, oregano preparation, and Yucca plant preparation are substantially as described above. The composition may further comprise at least one mineral nutrient, selected from at least one of selenium or zinc. As described above, the compositions may be formulated for admixing with a food, or for feeding as a dietary supplement.
  • In yet another aspect of the invention, a method for preventing or reducing harmful effects of a protozoal infection in an animal suffering from or exposed to a protozoal organism is provided, comprising administering a composition to the animal comprising a yeast cell wall and a preparation derived from oregano in an amount effective to prevent or reduce protozoal infection or cecal or liver lesions caused by protozoal infection. The compositions may be formulated for admixing with a food, or for feeding as a dietary supplement.
  • In still yet another aspect of the invention, a method for preventing or reducing harmful effects of a protozoal infection in an animal is provided, comprising administering a composition to the animal comprising a yeast cell wall, at least one preparation derived from oregano, and at least one plant preparation derived from Yucca in an amount effective to prevent or reduce protozoal infection or cecal lesions caused by protozoal infection.
  • As should be appreciated, the embodiments shown and described are an illustration of one of the modes best suited to carry out the invention. It will be realized that the invention is capable of modification in various, obvious aspects all without departing from the invention. Accordingly, the descriptions and examples provided herein will be regarded as illustrative in nature, and not as restrictive.
  • DETAILED DESCRIPTION OF THE INVENTION
  • As discussed above, it is desirable to provide compositions and methods for controlling protozoal parasitic infections in animals which are not drug-based, such as medicated feeds. To achieve this goal, and in accordance with the purposes of the present invention as described herein, novel compositions and methods for controlling protozoal parasitic infections are provided. In particular, the present invention provides novel compositions for controlling protozoal parasitic infections, comprising a yeast cell wall and a preparation derived from oregano. In one embodiment, the yeast cell wall includes at least one mannanoligosaccharide, and the oregano preparation is an oil. The compositions of this invention as described herein may be fed as supplements, or may be incorporated into commercially available foodstuffs. One of skill in the art will appreciate that the amounts of the composition fed will vary depending upon the animal species, the size of the animal, and the type of foodstuff to which the composition is added. The methods of the invention as described herein are suitable for preventing or reducing the harmful effects of protozoal parasitic infections in animals, including but not limited to, bovine, porcine, avian, equine, ovine, lapine, caprine, and aquatic species.
  • Typically, the yeast cell wall is prepared from a yeast organism using known methodology (see, Peppler, H. J. 1979. Production of yeasts and yeast products. Page 157 in: Microbial Technology & Microbial Processes, Vol. 1 (2d Ed.), Academic Press; incorporated herein by reference). Briefly, a yeast organism (typically S. cerevisiae strain NCYC 1026) is grown in accordance with common techniques used in food/beverage-related fermentations. Any of a number of common sugar-containing media, such as diluted molasses, may be used to provide a source of sugars for growth of the yeasts. Other suitable media include wood sugars, sulfite waste liquor, and whey. The yeast biomass may then be separated and washed by centrifugation.
  • After centrifugation, the organism may be lysed by common methods, such as autolysis and/or hydrolysis at room temperature and pressure. A protease such as papain or any of a number of alkaline or neutral proteases may be added during the lysis phase to accelerate solubilization of yeast proteins and prevent agglutination of intracellular components. Following lysis, the resultant yeast cell wall preparation may be washed, such as by centrifugation and resuspension in a wash solution, and concentrated. The concentrated cell wall may be dried by any suitable method, such as drum drying or spray drying, to form a hygroscopic, water-soluble product.
  • The Yucca preparation may be derived from a Yucca plant by any suitable method for deriving a liquid extract from the plant, such as by chopping, crushing, macerating, pressing, or grinding the Yucca plant and obtaining a liquid extract therefrom. Optionally, the bark of the Yucca may be removed prior to extracting the liquid. The liquid extract may be converted to powder form for storage and/or transport, such as by drying and optionally admixing with a suitable carrier, prior to addition to the compositions of the present invention.
  • Typically, an organic or chelated trace mineral formulation will be used. In one embodiment of the present invention, the Se component may be provided as an organic Se source (SEL-PLEX; Alltech, Inc., Nicholasville, Ky.) and the Zn component may be provided as BIOPLEX ZN (Alltech, Inc., Nicholasville, Ky.). However, it will be appreciated that any formulation of trace mineral suitable for provision as a food/feed ingredient or supplement may be used in the compositions of the present invention.
  • The following examples are presented for illustrative purposes only, and are not to be considered restrictive of the scope of the invention as otherwise described herein.
  • EXAMPLE 1
  • Anticoccidial efficacy of the compositions of the present invention in poultry was evaluated against a conventional coccidiostat, Salinomycin (60 g/1000 kg of feed). Three dietary treatments were prepared:
      • 1. Dietary treatment 1: yeast cell wall (1 kg/1000 kg feed), Yucca preparation (500 g/1000 kg feed), selenium (0.2 g/1000 kg feed), and zinc (20 g/1000 kg feed), included in feed at 1.9 kilograms/1000 kg feed.
      • 2. Dietary treatment 2: dietary treatment 1 plus 15 g/1000 kg feed of oregano preparation. The oregano preparation was prepared by steam distillation using methods known in the art to provide an oil, and was added to the dietary treatment as 25 g/1000 kg feed of a powder comprising 60% oregano oil on a synthetic silica carrier. Dietary treatment 2 was included in the feed at a rate of 1.925 kilograms/1000 kg feed.
      • 3. Dietary treatment 3: dietary treatment 1 with the Yucca preparation omitted, plus 30 g/ton of oregano preparation as described above, included in feed at a rate of 1.45 kilograms/1000 kg feed.
  • Day-old Cobb×Cobb poultry having an average starting body weight of 45 g were separated into cages. Each experimental treatment consisted of 8 cages, with 10 birds per cage (n=80 birds per experimental treatment). Experimental treatments were: (a) negative control (no dietary treatment and no coccidial challenge); (b) positive control (no dietary treatment but provided a coccidial challenge as described below); (c) dietary treatment 1 plus coccidial challenge; (d) dietary treatment 2 plus coccidial challenge; (e) dietary treatment 3 plus coccidial challenge; and (f) salinomycin treatment (60 g/1000 kg feed) plus coccidial challenge.
  • A coccidial inoculum was prepared, consisting of a mixed species culture of oocysts of Eimeria acervulina (60,000 oocysts), E. maxima (10,000 oocysts), and E. tenella (50,000 oocysts). The inoculum was delivered to birds receiving a coccidial challenge by oral gavage in a volume of 1 ml per bird in water.
  • On day 0 of the experiment, birds were weighed by cage and allocated to experimental treatments, and feed issued. After an acclimation period (day 14 of the experiment) the birds were weighed by cage and inoculated with the mixed coccidial infection. On day 20 of the experiment, birds were weighed by cage, and feed remaining was weighed. The birds were sacrificed, all bird intestinal lesions were scored, and litter oocysts counted.
  • Table 1 summarizes the effect of the present invention on live weight gain and feed conversion. The compositions of the invention (dietary treatments 2 and 3) provided significant increases in weight gain in inoculated birds, compared to nontreated and inoculated controls. There was no statistically significant effect on feed conversion.
  • TABLE 1
    The effect of treatments on average live weight gains (kg) and
    feed conversion ratios in chicks challenged with an Eimeria challenge#.
    Feed Feed
    Avg Live Weight Conversion Conversion
    Wt gain Day ratio ratio
    Treatment Challenge Day 14-20 0-20 Day 14-20 Day 0-20
    a No 318a .572a 1.444a 1.573a
    b Yes   .200c .463b 1.995b 1.839b
    c Yes   .214cd .462b 1.860b 1.827b
    d Yes   .225de .491bcd 1.847b 1.798b
    e Yes   .235e .474bcd 1.672c 1.748bc
    f Yes   .266b .522c 1.568ac 1.653ac
    n = 8 groups of 10 birds for each treatment.
    #= Different subscripts within a column denote treatment differences, (P < 0.05), as determined by Analysis of Variance and Tukey's pairwise Post Hoc analysis.
  • Similarly, the compositions of the present invention reduced the severity of intestinal lesions (Table 2) compared to nonmedicated, challenged groups. Lesion scores were observed and recorded according to the system of Johnson and Reid (Johnson, J. K., Reid, W. M. 1970. Anticoccidial drugs: lesion scoring techniques in battery and floor pen experiments with chickens. Exp. Parasitol. 28, 30-36; incorporated herein by reference), wherein 0 is normal and severity of lesions is ranked from 1-4, with 4 representing the most severe infection.
  • TABLE 2
    The effect of treatments on average lesion scores observed in the
    upper, middle and ceca sections of the intestine in chicks challenged with
    an Eimeria challenge#.
    Treatment Challenge Upper Middle Ceca Average
    a No 0a 0a 0a 0
    b Yes 2.0c 1.9c 2.6b 2.2
    c Yes 1.6b 1.7cd 2.1bc 1.8
    d Yes 1.5b 1.5ce 1.9dc 1.6
    e Yes 1.4b 1.4de 2.0dc 1.6
    f Yes 1.4b 0.8b 1.6dc 1.3
    n = 8 groups of 10 birds for each treatment.
    #= Different subscripts within a column denote treatment differences, (P < 0.05), as determined by Analysis of Variance and Tukey's pairwise Post Hoc analysis.
  • None of the dietary treatments had a statistically significant effect on litter oocyst counts (data not shown).
  • EXAMPLE 2
  • It was of interest to compare the effects of the compositions of the present invention on a variety of different protozoal parasites. Blackhead is an acute or chronic protozoan disease of fowl, primarily affecting the cecae and liver, caused by Histomonas meleagridis. Symptoms include loss of appetite, increased thirst, drowsiness, and diarrhea.
  • A total of 750 1 day old Hubbard Hi-Y broilers were used in this study. Animals were separated into 5 pens (150 birds per pen, day 0 average weight 40 g/broiler chick). Each pen contained 4 water fountains and 4 22 kg capacity feed tubes. Each pen had 2 inches of new wood shaving bedding top dressed with 1 inch of old bedding from a commercial broiler breeder flock, with the exception of a control pen which had 3 inches of new bedding only. The basal feed was a commercial corn-soy based diet. Starter feed was fed from day 0 to 21 of the experiment, and grower feed was fed from day 22 to 42. Diet 1 and diet 2 from Example 1 above were added to the basal diet as premixes (1.9 kg/ton). The conventional medicated feed premix Histostat (nitarsone, 170.3 g/ton) was added as a positive control. The basal diet composition is presented in Table 3.
  • TABLE 3
    Basal diet composition (lbs).
    INGREDIENT STARTER GROWER
    Yellow corn 7.5% 1081.6 1194.0
    Soy meal 47.5% 743.3 641.2
    AnVeg Fat Blend 81.7 80.0
    Limestone fine 39.2 36.1
    Salt 6.0 5.0
    Choline Cl 60% 1.5 0.9
    Trace mineral mix 1.4 0.8
    Vitamin premix 0.8 1.0
    Biofos 32.8 28.8
    Sodium bicarbonate 6.0 6.0
    Tribasic Cu Cl 0.5 0.5
    L-Lysine HCl 0.0 0.5
    DL-Meth 99% 4.3 4.2
    Se mix 1.0 1.0
    Total 2000 2000
  • To expose the broilers to H. meleagridis, litter was collected from a commercial broiler breeder flock and the presence of Heterakis gallinarum was verified. H. gallinarum (cecal worm) are known to shed H. meleagridis in their eggs. On days 7, 8, 9, 10, 11, and 12, contaminated litter was top dressed (approximately 2 pounds/pen/day) in 4 of the 5 pens. The fifth pen was kept as an unchallenged control. The animals were visually inspected daily for general health and response to challenge. After day 7, all animals were observed for clinical signs of infection. On days 28, 35, and 42, 25 randomly selected birds were euthanized, and cecal and liver lesions scored as follows:
  • Cecal Scores
    • 0—Normal;
    • 1—Slight thickening of cecal wall;
    • 2—Moderately thickened cecal wall or slight/moderate cecal core;
    • 3—Moderate thickening of cecal wall and cecal core;
    • 4—Ceca grossly enlarged due to presence of large cecal core.
    Liver Score
    • 0—Normal;
    • 1—Slight mottling of liver;
    • 2—Moderate mottling of liver;
    • 3—Concentrated areas of necrotic liver tissue.
  • Treatments (by pen) were: (1) non-challenged (with H. meleagridis) non-supplemented; (2) challenged but non-supplemented; (3) challenged and provided Histostat; (4) challenged and provided dietary treatment 1 as described in Example 1; and (5) challenged and provided dietary treatment 2 as described in Example 1. Results are presented in Tables 4-9.
  • TABLE 4
    Pen feed consumption (kg).
    Treatment Day 28 Day 35 Day 42
    1 201.9 291.7 412.7
    2 192.4 238.1 354.7
    3 177.6 221.4 336.8
    4 196.5 253.2 354.3
    5 203.8 267.4 372.0
  • TABLE 5
    Average weight/bird (kg).
    Treatment Day 28 Day 35 Day 42
    1 0.871 1.362 1.709
    2 0.768 1.183 1.612
    3 0.786 1.334 1.860
    4 0.874 1.326 1.871
    5 0.870 1.221 1.683
  • TABLE 6
    Feed efficiency.
    Treatment Day 28 Day 35 Day 42
    1 1.622 1.854 2.547
    2 1.884 2.101 2.697
    3 2.150 2.066 2.717
    4 1.772 1.902 2.152
    5 1.662 1.906 2.125
  • TABLE 7
    Mortality (%).
    Treatment Day 28 Day 35 Day 42
    1 0.00 3.33 8.00
    2 6.00 16.00 16.67
    3 24.67 26.67 26.67
    4 10.67 13.33 13.33
    5 1.33 3.33 3.33
  • TABLE 8
    Average cecal lesion scores.
    Treatment Day 28 Day 35 Day 42
    1 0.080a 0.080a 0.200a
    2 1.840c 1.560c 1.560d
    3 1.040b 0.640b 0.960c
    4 0.880b 0.960b 0.720b,c
    5 0.760b 0.640b,c 0.440a,b
  • TABLE 9
    Average liver lesion scores.
    Treatment Day 28 Day 35 Day 42
    1 0.000a 0.000a 0.000a
    2 0.760b 1.160c 0840b
    3 0.000a 0.000a 0.040a
    4 0.040a 0.320b 0.080a
    5 0.040a 0.240b 0.000a
  • Feed consumption was greatest for the unchallenged group and lowest for the group provided Histostat. Feed efficiency, calculated as feed consumption through a period by weight gained, was greatest in the unchallenged group through days 28 and 35. Feed efficiency was greatest on day 42 in the group provided dietary treatment 2. At each day observed, mortality was lowest in the unchallenged group and in the group provided dietary treatment 2. On day 42, cecal lesions were significantly higher in the group provided Histostat than in the group provided dietary treatment 2. Cecal lesions were less severe in birds provided the composition of the present invention in comparison to the birds receiving Histostat. The results of the present experiment suggest that birds challenged with H. meleagridis and provided the compositions of this invention performed in a similar manner as birds provided a commercial medicated feed, and significantly better than untreated challenged birds.
  • EXAMPLE 3
  • Cochlosoma anatis is a flagellated protozoan parasite of birds, which is considered a primary source of loss performance and mortality in turkeys. The purpose of this experiment was to compare the effects of the compositions of the present invention to conventional treatments for C. anatis, specifically Histostat (170.3 g/ton of feed) and monensin (72 g/ton of feed) provided as premixes.
  • A total of 360 1 day old Hybrid turkey hens were used in this study. Animals were separated into 36 pens (10 birds per pen). With the exception of the unchallenged controls, each pen had 2 inches of new wood shaving bedding top dressed with 1 inch of old bedding from a commercial turkey flock known to have had coccidiosis, to promote industry conditions. The basal feed was a commercial corn-soy based diet (Table 10). Diet 1 and diet 2 from Example 1 above were added to the basal diet as premixes (1.9 kg/ton). All birds and feeds were weighed on days 0, 7, 14, and 21.
  • TABLE 10
    Basal diet composition.
    INGREDIENT STARTER (%)
    Corn meal 41.54
    Soy meal 48.78
    AnVeg Fat Blend 4.09
    Limestone 1.35
    Dical 21/18.5% 3.10
    Salt 0.10
    TBCC 0.03
    Choline Cl 0.15
    Vitamin premix 0.05
    Sodium bicarbonate 0.20
    Mineral premix 0.10
    L-Lysine HCl 0.19
    DL-Meth 99% 0.28
    Se mix 0.05
  • C. anatis inoculum was prepared as follows:
      • 1. A frozen isolate was thawed at 37° C.
      • 2. Thawed isolate was suspended in phosphate buffer (10-20 ml).
      • 3. Fifteen one-day-old poults, identified as “first passage” poults, were each orally inoculated with 1.5 ml of the inoculum and placed in clean batter pens for 7 days.
      • 4. On day 7 post-inoculation, the poults were feed fasted for 6 hours, euthanized, and their jejunum and ileum removed.
      • 5. Intestinal mucosa from the euthanized poults was scraped into a collection flask containing phosphate buffer.
      • 6. 30 healthy 7 day old poults (“second passage” poults) were inoculated with 2 ml of the intestinal scraping/buffer mixture and placed in clean battery pens for 7 days.
      • 7. On day 7 post inoculation, the “second passage” poults were feed fasted for 6 hours, euthanized, and their jejunum and ileum removed.
      • 8. Intestinal mucosa from the euthanized “second passage” poults was scraped into a collection flask containing phosphate buffer.
      • 9. The intestinal scrapings were homogenized by repeated passage through a syringe with 20 gauge needle, and the material was coarse filtered through sterile gauze.
      • 10. The number of C. anatis per ml in this second pass material was counted by hemacytometer.
      • 11. The homogenate was then diluted with phosphate buffer such that a 1 ml dose contained approximately 2×106 C. anatis.
      • On day 14 of the experimental period, C. anatis was delivered in a 1 ml volume to each poult except those in the unchallenged control group.
      • On day 21, all birds were weighed and euthanized. The entire intestinal tract was removed and scored on a scale of 0-4 based on severity of lesions as follows:
    • 0—no lesions;
    • 1—slight observations of sloughed/flattened tissue areas within the lumen or of “enteritis like” lesions around the diverticulum;
    • 2—minimal observations of sloughed/flattened tissue areas within the lumen or of “enteritis like” lesions around the diverticulum;
    • 3—moderate observations of sloughed/flattened tissue areas within the lumen or of “enteritis like” lesions around the diverticulum;
    • 4—severe observations of sloughed/flattened tissue areas within the lumen or of “enteritis like” lesions around the diverticulum.
  • Treatments (by pen) were: (1) non-challenged (with C. anatis) non-supplemented; (2) challenged non-supplemented; (3) challenged and provided Histostat; (4) challenged and provided monensin; (5) challenged and provided dietary treatment 1 from Example 1; and (6) challenged and provided dietary treatment 2 from Example 1. Results are presented in Tables 11-15.
  • TABLE 11
    Average weight gain (g).
    Treatment Day 7 Day 14 Day 21
    1 45.8b 182.3a 245.0a
    2 54.2ab 174.5ab 202.3b
    3 64.2a 174.2ab 229.2a
    4 53.3ab 160.0b 225.0a
    5 51.7ab 178.3ab 228.3a
    6 60.8ab 181.7a 245.8a
  • TABLE 12
    Feed Efficiency (Feed intake/Weight gain).
    Treatment Day 7 Day 14 Day 21 Day 21*
    1 1.254b 1.490a 1.625a 1.625a
    2 1.136ab 1.474ab 1.906a 1.880b
    3 1.130a 1.505ab 1.716a 1.679a
    4 1.170ab 1.544b 1.689a 1.619a
    5 1.183ab 1.523ab 1.744a 1.664a
    6 1.134ab 1.493a 1.621a 1.621a
    *Feed efficiency at day 21, adjusted for mortality by adding weight gain of dead to pen weight gain.
  • TABLE 13
    Mortality (%).
    Treatment Day 7 Day 14 Day 21
    1 0.00 0.00 0.00
    2 0.00 0.00 1.67
    3 0.00 0.00 1.67
    4 0.00 0.00 3.33
    5 0.00 0.00 5.00
    6 0.00 0.00 0.00
  • TABLE 14
    Average C. anatis lesion scores.
    Treatment Day 21
    1 0.233a
    2 2.061c
    3 1.300bc
    4 1.150b
    5 1.400bc
    6 1.083ab
  • As expected, at day 21 the untreated, challenged group had inferior weight gain compared to other groups. Greatest weight gain was seen on day 21 in the turkeys provided diet 2, significantly greater than challenged, untreated birds. The birds provided diet 2 had the fewest C. anatis lesions of any of the groups studied. Accordingly, the compositions of the present invention gave similar results in comparison to conventional medicated preparations for treatment of C. anatis.
  • It is accordingly shown herein that the present invention provides suitable compositions and methods for control or reduction of harmful effects of various protozoal parasites of animals. The compositions are efficacious, and provide a level of control of protozoal infections comparable to that of conventional drug-based treatments.
  • The foregoing description of the preferred embodiment of this invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Obvious modifications or variations are possible in light of the above teachings. The embodiment was chosen and described to provide the best illustration of the principles of the invention and its practical application to thereby enable one of ordinary skill in the art to utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated.
  • All such modifications and variations are within the scope of the invention as determined by the appended claims when interpreted in accordance with the breadth to which they are fairly, legally, and equitably entitled.

Claims (34)

What is claimed is:
1. A composition for preventing or reducing harmful effects of a protozoal infection in an animal suffering from or exposed to a protozoal organism, the composition comprising a yeast cell wall and a preparation derived from oregano.
2. The composition of claim 1, whereby the composition is formulated for admixing with a food or animal feed.
3. The composition of claim 1, whereby the composition is formulated for feeding as a dietary supplement.
4. The composition of claim 1, wherein the oregano preparation is an oil derived from oregano.
5. The composition of claim 1, wherein the composition comprises at least one yeast-derived mannanoligosaccharide.
6. The composition of claim 5, wherein the mannanoligosaccharide-containing composition is formulated for feeding to bovine, porcine, avian, equine, ovine, lapine, caprine, and aquatic species.
7. The composition of claim 1, wherein the yeast is derived from a species selected from the group consisting of Saccharomyces, Candida, Kluyveromyces and Torulaspora.
8. The composition of claim 7, wherein the yeast is derived from Saccharomyces cerevisiae.
9. The composition of claim 8, wherein the yeast is derived from Saccharomyces cerevisiae strain NCYC 1026.
10. The composition of claim 1, wherein the composition comprises dried cells of yeast.
11. The composition of claim 6, wherein the animal is an avian species.
12. The composition of claim 11, wherein the avian species is a chicken, turkey, duck, goose, pheasant, quail or a companion bird.
13. The composition of claim 1, wherein the composition further comprises at least one mineral nutrient.
14. The composition of claim 13, wherein the mineral nutrient comprises at least one of selenium or zinc.
15. The composition of claim 1, wherein the composition further comprises at least one preparation derived from a Yucca plant.
16. The composition of claim 14, wherein the Yucca plant preparation is derived by chopping, crushing, macerating, pressing, or grinding the Yucca plant to obtain an extract.
17. The composition of claim 10, wherein the protozoal organism is selected from the group consisting of Eimeria species, Histomonas species, Cochlosoma species, Hexamita species, and any combination thereof.
18. A composition for preventing or reducing harmful effects of a protozoal infection in an animal, the composition comprising a yeast cell wall, at least one preparation derived from oregano, and at least one plant preparation derived from Yucca.
19. The composition of claim 18, wherein the composition comprises at least one yeast-derived mannanoligosaccharide.
20. The composition of claim 18, wherein the yeast is derived from a species selected from the group consisting of Saccharomyces, Candida, Kluyveromyces and Torulaspora.
21. The composition of claim 20, wherein the yeast is derived from Saccharomyces cerevisiae.
22. The composition of claim 21, wherein the yeast is derived from Saccharomyces cerevisiae strain NCYC 1026.
23. The composition of claim 18, wherein the Yucca plant preparation is derived by chopping, crushing, macerating, pressing, or grinding the Yucca plant to obtain an extract.
24. The composition of claim 18, further comprising at least one mineral nutrient.
25. The composition of claim 24, wherein the mineral nutrient comprises at least one of selenium or zinc.
26. The composition of claim 18, wherein the oregano preparation is an oil derived from oregano.
27. The composition of claim 18, whereby the composition is formulated for admixing with a food or animal feed.
28. The composition of claim 18, whereby the composition is formulated for feeding as a dietary supplement.
29. A method for preventing or reducing harmful effects of a protozoal infection in an animal suffering from or exposed to a protozoal organism, comprising administering a composition to the animal comprising a yeast cell wall and a preparation derived from oregano in an amount effective to prevent or reduce protozoal infection or cecal lesions caused by protozoal infection.
30. The method of claim 29, whereby the composition is formulated for admixing with a food.
31. The method of claim 29, whereby the composition is formulated for feeding as a dietary supplement.
32. A method for preventing or reducing harmful effects of a protozoal infection in an animal, comprising administering a composition to the animal comprising a yeast cell wall, at least one preparation derived from oregano, and at least one plant preparation derived from Yucca in an amount effective to prevent or reduce protozoal infection or cecal lesions caused by protozoal infection.
33. The method of claim 32, whereby the composition is formulated for admixing with a food or animal feed.
34. The method of claim 32, whereby the composition is formulated for feeding as a dietary supplement.
US11/571,053 2004-06-25 2004-07-21 Methods and compositions for controlling parasitic infections of animals Active 2029-02-09 US8992999B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/571,053 US8992999B2 (en) 2004-06-25 2004-07-21 Methods and compositions for controlling parasitic infections of animals

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52172904P 2004-06-25 2004-06-25
US11/571,053 US8992999B2 (en) 2004-06-25 2004-07-21 Methods and compositions for controlling parasitic infections of animals
PCT/US2004/023478 WO2006022616A1 (en) 2004-07-21 2004-07-21 Methods and compositions for controlling parasitic infections of animals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/186,840 Continuation US20080291903A1 (en) 2003-09-08 2008-08-06 Subscriber line circuit for communication systems and communication system

Publications (3)

Publication Number Publication Date
US20080008767A1 US20080008767A1 (en) 2008-01-10
US20140147515A2 true US20140147515A2 (en) 2014-05-29
US8992999B2 US8992999B2 (en) 2015-03-31

Family

ID=38951735

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/571,053 Active 2029-02-09 US8992999B2 (en) 2004-06-25 2004-07-21 Methods and compositions for controlling parasitic infections of animals

Country Status (1)

Country Link
US (1) US8992999B2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200706594T2 (en) * 2005-03-31 2008-01-21 Improcrop U.S.A, Inc. Resistance to abiotic stress in plants.
WO2012118993A1 (en) * 2011-03-01 2012-09-07 Oms Investments, Inc. Wild bird food essential nutrition products
EP3138573A1 (en) * 2015-07-09 2017-03-08 Danstar Ferment AG Compositions and methods for stimulating immune responses in human and/or animal
CN113261616A (en) * 2021-04-27 2021-08-17 内蒙古优然牧业有限责任公司 Feed additive containing yucca, and preparation method and application thereof
WO2023193124A1 (en) * 2022-04-08 2023-10-12 Plantae Labs Spa Coated concentrated composition and uses thereof, useful for controlling gastrointestinal diseases in birds and improving productive parameters

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3615679A (en) * 1968-10-31 1971-10-26 Buitoni Foods Corp Frozen pizza and dough
US4167579A (en) * 1976-08-06 1979-09-11 Hoffmann-La Roche Inc. Antibiotic X-14547 and its use for increasing feed efficiency in ruminants
US4356264A (en) * 1980-04-11 1982-10-26 International Minerals & Chemical Corp. Zinc-containing antibiotic agents
JPS61118189A (en) 1984-11-12 1986-06-05 Masazumi Takebe Method for accelerating action of microbe
EP0195870B1 (en) 1985-03-22 1990-01-31 Laboratoires BIOCODEX Use of saccharomyces yeast in the manufacture of a medicament against amoebiasis
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
CN1027952C (en) 1989-10-13 1995-03-22 蒋祥太 Additives poultry composite feed and their production method
JPH04278070A (en) 1991-02-28 1992-10-02 Shokuhin Sangyo Chokoatsu Riyou Gijutsu Kenkyu Kumiai Bacteriostat
US5300491A (en) * 1991-10-31 1994-04-05 Apothekernes Laboratorium A.S. Treatment of protozoal infection
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5597807A (en) * 1994-08-01 1997-01-28 University Of Saskatchewan Quinoa saponin compositions and methods of use
HUP9900312A3 (en) 1995-05-26 2001-04-28 Ropapharm B V Pharmaceutical compositions, based on etheric oils obtained from plants for use in the human and veterinary medical field
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
JPH09187229A (en) 1996-01-10 1997-07-22 Idemitsu Material Kk Feed composition for poultry
AUPO430496A0 (en) 1996-12-19 1997-01-23 Arnott's Biscuits Limited Prebiotics and probiotics
DK0904780T3 (en) 1997-09-30 2004-02-23 D & W Trading B V Use of pharmaceutical compositions comprising thymol and / or carvacrol against histomoniasis
US5955086A (en) 1998-06-18 1999-09-21 Biotics Research Corporation Oregano for the treatment of internal parasites and protozoa
MXPA03003996A (en) * 2000-11-08 2004-05-05 Novus Int Inc Methods and compositions for the control of coccidiosis.
WO2002085415A1 (en) 2001-04-17 2002-10-31 Biomatrix, Inc Non-digestible sugar-coated products and process
US7048937B2 (en) 2001-07-27 2006-05-23 Alltech, Inc. Methods and compositions for control of coccidiosis
US20040052905A1 (en) * 2002-09-18 2004-03-18 Aliments Breton Inc. Animal feed in granular form and process of preparing same
US20050058671A1 (en) 2003-05-09 2005-03-17 Bedding Peter M.J. Dietary supplement and method for treating digestive system-related disorders
US7416742B2 (en) * 2004-06-16 2008-08-26 Sartec Corporation Methods and compositions for controlling microorganism populations in the digestive system of animals
US20090263416A1 (en) 2006-06-16 2009-10-22 Dawson Karl A Reduction of antibiotic resistance in bacteria

Also Published As

Publication number Publication date
US20080008767A1 (en) 2008-01-10
US8992999B2 (en) 2015-03-31

Similar Documents

Publication Publication Date Title
AU2021202307B2 (en) Combination, composition, and method of administering the combination or composition to animals
Bolder et al. The effect of flavophospholipol (Flavomycin) and salinomycin sodium (Sacox) on the excretion of Clostridium perfringens, Salmonella enteritidis, and Campylobacter jejuni in broilers after experimental infection
CA2455595C (en) Compositions of yeast cell walls and mannanoligosaccharides for control of coccidiosis
EP1103190B1 (en) Feed for prevention and/or treatment of coccidiosis
US20170106027A1 (en) Compositions and methods of improving performance and intestinal health of poultry
AU2002319730A1 (en) Methods and compositions for control coccidiosis
US8992999B2 (en) Methods and compositions for controlling parasitic infections of animals
EP1768491B1 (en) Composition and its use for controlling protozoal infections of animals
Awaad et al. Heat stress impedance by acidifiers in broiler chickens
US20150037439A1 (en) Phytogenic nutraceutical composition and methods of use thereof
Pathak et al. Influence of Haemonchus contortus infection on nutrient intake and its utilization in kids fed different levels of nutrition
Ashraf Evaluation of therapeutic and prophylactic potentials of toltrazuril against caecal coccidiosis of chickens in Bangladesh
JP2023545650A (en) Anticoccidial composition containing coumaric acid and its use
Castle et al. PSVII-11 Survey of Disease, Management and Biosecurity Practices of Hawaii Swine Farmers.
JP2023532029A (en) Potential positive effects of animal diets for the prevention and treatment of coccidiosis
JP2023543229A (en) Anti-coccidiosis compositions containing stilbene compounds and their uses
KR20130053585A (en) A compositions for preventing or treating coccidiosis comprising dang gui
Khanagwal et al. Effect of Supplemental Levels of Calcium and Zinc on Energy Metabolizability and Nitrogen Retention in Broilers Exposed to Mixed Coccidiosis
Francesch et al. Performance of broilers vaccinated for coccidiosis and fed low or high non-starch-polysaccharides diets with or without enzyme addition.
Gornowicz et al. Selected performance traits in broiler chickens fed on diet with or without added Diclazuril preparation and compared with those in broiler chickens from parent stock hens vaccinated with Eimeria subunits

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLTECH, INC., KENTUCKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DUFFY, CEPTA;REEL/FRAME:021562/0459

Effective date: 20040820

AS Assignment

Owner name: ALLTECH, INC., KENTUCKY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONNOLY, AIDAN;REEL/FRAME:021835/0312

Effective date: 20081113

AS Assignment

Owner name: COOPERATIEVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.

Free format text: SECURITY AGREEMENT;ASSIGNOR:ALLTECH, INC.;REEL/FRAME:024588/0605

Effective date: 20100618

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS SUCCESSOR ADMINISTRATIVE

Free format text: INTELLECTUAL PROPERTY SECURITY INTEREST ASSIGNMENT AGREEMENT (PATENTS);ASSIGNOR:COOPERATIEVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A., "RABOBANK NEDERLAND", NEW YORK BRANCH, AS RESIGNING ADMINISTRATIVE AGENT;REEL/FRAME:031226/0827

Effective date: 20130913

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

AS Assignment

Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT, DELAWARE

Free format text: ASSIGNMENT FOR SECURITY -- PATENTS;ASSIGNORS:ALLTECH, INC;RIDLEY USA, INC;REEL/FRAME:052694/0412

Effective date: 20200518

AS Assignment

Owner name: RIDLEY USA INC., MINNESOTA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT;REEL/FRAME:057919/0761

Effective date: 20211015

Owner name: ALLTECH, INC., KENTUCKY

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT;REEL/FRAME:057919/0761

Effective date: 20211015

AS Assignment

Owner name: ALLTECH, INC., KENTUCKY

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS (4);ASSIGNOR:BANK OF AMERICA, N.A., AS SUCCESSOR AGENT TO COOPERATIVE CENTRALE RAIFFEISEN-BOERENLEENBANK B.A., "RABOBANK NEDERLAND", NEW YORK BRANCH, AS ADMINISTRATIVE AGENT;REEL/FRAME:058282/0535

Effective date: 20211015

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT, CALIFORNIA

Free format text: PATENT SECURITY AGREEMENT;ASSIGNOR:ALLTECH, INC.;REEL/FRAME:058292/0934

Effective date: 20211015

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8